Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00731705
Other study ID # 0612-01/ IUCRO-0180
Secondary ID
Status Withdrawn
Phase N/A
First received August 7, 2008
Last updated September 18, 2014
Start date January 2007
Est. completion date January 2010

Study information

Verified date September 2014
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The doctors in the Bone Marrow Transplant Service at the Indiana University Cancer Center are working to better understand how the immune cells that cause graft-versus-host disease (a major complication of stem cell transplantation in which the donor immune cells attack the patient's organs) can be selectively removed from the graft, leaving other immune cells that fight infections.


Description:

The purpose of this research is to study how immune cells (called T cells) that cause graft-versus-host disease (GVHD) can best be selectively separated from other T cells and removed from the cells that will be returned to the cancer patient's body. These other T cells may protect against infection when given to patients after a stem cell transplant. The removal of cells that cause GVHD would allow doctors to safely give back the T cells that protect against infection, without the risk of GVHD.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2010
Est. primary completion date January 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with hematological malignancies who are undergoing evaluation for autologous or allogeneic stem cell transplants will be eligible, if: (1)They have no circulating neoplastic cells in the peripheral blood as assessed by routine morphology or flow cytometry. (2)Patients with acute myeloid or lymphocytic leukemia are in complete remission

- First-degree relatives of patients evaluated for stem cell transplantation will be eligible if: (1) Willing to undergo testing for HIV and hepatitis B and C (free of charge) (2) Not pregnant at time of collection of blood (3)In good general health (4) No prior history of malignancy. (5) Age 18 years or older if donating apheresis product. (Because of the relatively invasive nature of the leukopheresis procedure and difficulties in obtaining consent, children <18 who are first degree relatives of the patient will not undergo apheresis for studies on this protocol)

- Written informed consent

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Procedure:
collection of peripheral blood and apheresis samples
Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Indiana University School of Medicine National Institutes of Health (NIH)

Outcome

Type Measure Description Time frame Safety issue
Primary To develop the optimum conditions for activating the maximum number of alloreactive T cells from clinical scale samples 5 years No
Secondary To develop a GMP grade high throughput, flow through immunomagnetic cell separation system for clinical scale depletion of alloreactive T cell, capable of t3log10 depletion of alloreactivity while retaining >80% third party reactivity. 5 years No
See also
  Status Clinical Trial Phase
Recruiting NCT05433090 - An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies N/A
Completed NCT00061620 - Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies Phase 1
Enrolling by invitation NCT02473757 - Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Not yet recruiting NCT06296368 - DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics N/A
Recruiting NCT02032446 - Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease Phase 1/Phase 2
Recruiting NCT02884375 - Elderly CAncer Patient N/A
Recruiting NCT01203722 - Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Phase 1/Phase 2
Completed NCT00780052 - Infusional C-myb ASODN in Advanced Hematologic Malignancies Phase 1
Recruiting NCT04098393 - Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation Phase 1
Recruiting NCT06028828 - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT04538599 - RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies Phase 1
Completed NCT03609827 - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed NCT01380756 - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia Phase 1
Recruiting NCT05849207 - Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant Phase 1
Not yet recruiting NCT05028478 - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT02494258 - A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders Phase 2
Completed NCT03212560 - Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
Active, not recruiting NCT02600208 - Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device Phase 2/Phase 3
Completed NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Phase 1/Phase 2
Completed NCT01949545 - Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment Phase 1

External Links